Cognitive Enhancement as a Target for Cocaine Pharmacotherapy
What is the purpose of this trial?
Specific Aim #1: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in reducing cocaine use as measured by cocaine urine results and self-report days of use.
Specific Aim # 2: To determine if galantamine (8 or 16 mg/day) is more effective than placebo in improving attention, assessed with the Rapid Visual Information Processing (RVIP) and the Simple Reaction Time (SRT) tests Specific Aim # 3: To determine if improvement in attention during the first four weeks of treatment will mediate galantamine's efficacy in reducing cocaine use.
- 18 Years - 55 Years
- National Institute on Drug Abuse (NIDA)
- September 2011
- Last Updated:
- December 11, 2013
- Study HIC#:
Clinicaltrials.gov ID: NCT01531153